桂枝茯苓胶囊原料药及其组分对人源乳腺癌细胞株增殖的影响

Effect of Guizhi Fuling Capsule and Its Ingredients on Human Breast Cancer Cells Proliferation

目的利用高通量筛选技术,观察桂枝茯苓胶囊原料药及其组分对人源乳腺癌细胞株增殖的作用。方法桂枝茯苓胶囊原料药经萃取、洗脱后获得的粗组分,再经分离得到929种标准组分。采用磺酰罗丹明B比色法评价以含1%DMSO的无血清DMEM培养液体系为对照时桂枝茯苓胶囊原料药(6.125、12.5、25、50、100、200、400μg/mL)及其929种组分(50、5μg/mL)对人源乳腺癌细胞株MCF-7和MDAMB-231增殖的影响。结果作用72h后,高浓度的桂枝茯苓胶囊原料药对MCF-7细胞的增殖抑制能力强,且有良好量效关系(r=0.987 5),低浓度对MDA-MB-231细胞增殖抑制能力强;929个组分(5μg/mL)中仍有部分样品对乳腺癌细胞细胞生长抑制率>50%,同时这些组分对正常人脐静脉内皮细胞无生长抑制作用。结论桂枝茯苓胶囊原料药在两种人源乳腺癌细胞株上均有显著的抑制细胞增殖作用,并具有明显的浓度和时间依赖性。

Objective To evaluate the effect of Guizhi Fuling Capsule active pharmaceutical in- gredient （API） and its fractions on human breast cancer cells proliferation by high-throughput screening assay. Methods The crude fractions were obtained from the extraction and elution of Guizhi Fuling Cap- sule API, and 929 standard fractions were obtained by the optimal separation conditions. Sulforhodamine B （SRB） method was used to evaluate the effects of Guizhi Fuling Capsule API（6. 125, 12.5, 25, 50, 100,200,400 i^g/mL） and 929 kinds of fractions （50, 5 i^g/mL） on the proliferation of human breast cancer cells MCF-7 and MDA-MB-231 while the serum-free DMEM medium with 1% DMSO was used as blank control. Results The Guizhi Fuling Capsule API had a strong ability to inhibit the proliferation of MCF-7 cells at high concentration with significant concentration-dependent manner（r =0. 987 5） and the ability to inhibit the proliferation of MDA-MB-231 cells at low concentration following 72 hours treatment; some samples of 929 fractions （5 i^g/mL） were found to have a breast cancer cell growth inhibition rate above 50%, without toxicity on HUVECs proliferation. Conclusion The API of Guizhi Fuling Capsule had significant cytotoxicity effects on two human breast cancer cell lines, with significant concentration-and time-dependent manner.